Today, the President & CEO of Cryolife (NYSE: CRY), James Mackin, sold shares of CRY for $1.42M.
Following James Mackin’s last CRY Sell transaction on March 04, 2016, the stock climbed by 22.0%. In addition to James Mackin, 6 other CRY executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $68.5 million and quarterly net profit of $224K. In comparison, last year the company earned revenue of $47.82 million and had a net profit of $3.1 million. Currently, Cryolife has an average volume of 204.1K.
The insider sentiment on Cryolife has been negative according to 87 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
James Mackin’s trades have generated a 34.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
